According to Zacks, “BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents. BioNano Genomics, Inc. is based in San Diego, United States. “
Several other brokerages have also weighed in on BNGO. Maxim Group upgraded shares of BioNano Genomics to a “buy” rating and set a $11.00 price objective on the stock in a report on Wednesday, March 6th. Roth Capital reiterated a “buy” rating on shares of BioNano Genomics in a report on Tuesday, February 5th.
Shares of BNGO stock remained flat at $$3.15 during trading hours on Friday. 3,760 shares of the stock traded hands, compared to its average volume of 15,716. The stock has a market cap of $31.83 million and a price-to-earnings ratio of -1.21. BioNano Genomics has a 1-year low of $2.71 and a 1-year high of $10.00. The company has a debt-to-equity ratio of 3.13, a quick ratio of 4.85 and a current ratio of 5.94.
BioNano Genomics (NASDAQ:BNGO) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.12). The firm had revenue of $1.85 million for the quarter, compared to analyst estimates of $1.76 million. As a group, equities analysts expect that BioNano Genomics will post -2.25 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in BioNano Genomics in the fourth quarter valued at approximately $254,000. Worth Venture Partners LLC raised its holdings in BioNano Genomics by 1,666.6% in the fourth quarter. Worth Venture Partners LLC now owns 79,902 shares of the company’s stock valued at $417,000 after buying an additional 75,379 shares during the period. Monashee Investment Management LLC raised its holdings in BioNano Genomics by 50.6% in the fourth quarter. Monashee Investment Management LLC now owns 245,860 shares of the company’s stock valued at $1,288,000 after buying an additional 82,595 shares during the period. Finally, Sio Capital Management LLC raised its holdings in BioNano Genomics by 7.1% in the first quarter. Sio Capital Management LLC now owns 1,538,424 shares of the company’s stock valued at $4,629,000 after buying an additional 101,963 shares during the period. Hedge funds and other institutional investors own 10.33% of the company’s stock.
About BioNano Genomics
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Further Reading: What Does a Sell-Side Analyst Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.